CN109069875B - 产生免疫耐受反应的组合物和方法 - Google Patents

产生免疫耐受反应的组合物和方法 Download PDF

Info

Publication number
CN109069875B
CN109069875B CN201780015637.XA CN201780015637A CN109069875B CN 109069875 B CN109069875 B CN 109069875B CN 201780015637 A CN201780015637 A CN 201780015637A CN 109069875 B CN109069875 B CN 109069875B
Authority
CN
China
Prior art keywords
tgf
cells
beta
cell
aftgf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201780015637.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN109069875A (zh
Inventor
S·科恩
A·蒙索尼克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BG Negev Technologies and Applications Ltd
Original Assignee
BG Negev Technologies and Applications Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BG Negev Technologies and Applications Ltd filed Critical BG Negev Technologies and Applications Ltd
Publication of CN109069875A publication Critical patent/CN109069875A/zh
Application granted granted Critical
Publication of CN109069875B publication Critical patent/CN109069875B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201780015637.XA 2016-01-07 2017-01-05 产生免疫耐受反应的组合物和方法 Expired - Fee Related CN109069875B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662275827P 2016-01-07 2016-01-07
US62/275,827 2016-01-07
PCT/IL2017/050013 WO2017118979A1 (en) 2016-01-07 2017-01-05 Compositions and methods for generating immunotolerant responses

Publications (2)

Publication Number Publication Date
CN109069875A CN109069875A (zh) 2018-12-21
CN109069875B true CN109069875B (zh) 2021-12-24

Family

ID=59273512

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780015637.XA Expired - Fee Related CN109069875B (zh) 2016-01-07 2017-01-05 产生免疫耐受反应的组合物和方法

Country Status (7)

Country Link
US (1) US11123404B2 (enExample)
EP (1) EP3400074B1 (enExample)
JP (1) JP7033066B2 (enExample)
KR (1) KR20180104646A (enExample)
CN (1) CN109069875B (enExample)
IL (1) IL260436B2 (enExample)
WO (1) WO2017118979A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA035413B1 (ru) 2013-06-13 2020-06-10 Ордженисис Лтд. Популяции клеток, способы трансдифференцировки и способы их применения
MA41296A (fr) 2014-12-30 2017-11-07 Orgenesis Ltd Procédés de transdifférenciation et procédés d'utilisation de ceux-ci
SG11201911256UA (en) 2017-05-08 2020-01-30 Orgenesis Ltd Transdifferentiated cell populations and methods of use thereof
WO2019171377A1 (en) * 2018-03-06 2019-09-12 Orgenesis Inc Three dimensional clusters of transdifferentiated cells, compositions and methods thereof
JP2022506154A (ja) * 2018-11-01 2022-01-17 バークレー ライツ，インコーポレイテッド マイクロ流体環境において生体細胞をアッセイする方法
CN109771638A (zh) * 2018-12-28 2019-05-21 中国人民解放军陆军军医大学第一附属医院 一种免疫耐受剂
WO2024080183A1 (ja) * 2022-10-14 2024-04-18 国立大学法人東海国立大学機構 糖鎖複合体、薬物担体、及びドラッグデリバリーシステム

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007043050A2 (en) * 2005-10-11 2007-04-19 Ben-Gurion University Of The Negev Research And Development Authority Bioconjugates comprising sulfated polysaccharides and their uses
CN103002915A (zh) * 2010-04-13 2013-03-27 免疫创新治疗有限公司 抑制Treg细胞的方法和组合物
US9125883B2 (en) * 2004-06-14 2015-09-08 Institut Francais De Recherche Pour L'exploitation De La Mer (Ifremer) Sulfated depolymerized derivatives of exopolysaccharides (EPS) from mesophilic marine bacteria, method for preparing same, and uses thereof in tissue regeneration
CN105611937A (zh) * 2013-06-18 2016-05-25 复制细胞生命科学公司 治疗皮肤的组合物和方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4178361A (en) 1973-09-10 1979-12-11 Union Corporation Sustained release pharmaceutical composition
US5100668A (en) 1988-06-14 1992-03-31 Massachusetts Institute Of Technology Controlled release systems containing heparin and growth factors
IL118376A0 (en) 1996-05-22 1996-09-12 Univ Ben Gurion Polysaccharide sponges for cell culture and transplantation
GB9722604D0 (en) 1997-10-28 1997-12-24 Cancer Res Campaign Tech Heparin-binding growth factor derivatives
US6388060B1 (en) 1998-11-06 2002-05-14 Vascular Therapeutics Inc. Process for the sulfation of uronic acid-containing polysaccharides
JP2002542301A (ja) 1999-04-22 2002-12-10 アイトゲネシッシェ、テヒニッシェ、ホッホシューレ（エーテーハー） ヘパリン含有マトリックスからの増殖因子の制御放出
WO2001066164A1 (en) 1999-04-22 2001-09-13 Eidgenossisch Technische Hochschule Zurich Modified protein matrices
US6479064B1 (en) 1999-12-29 2002-11-12 Children's Medical Center Corporation Culturing different cell populations on a decellularized natural biostructure for organ reconstruction
US6773723B1 (en) 2000-08-30 2004-08-10 Depuy Acromed, Inc. Collagen/polysaccharide bilayer matrix
GB0029847D0 (en) 2000-12-07 2001-01-24 Univ Bristol Preparation of spheroids
DE60236974D1 (de) 2001-07-26 2010-08-19 Transparent Inc Kultiviertes Zellkonstrukt mit Sphäroiden kultivierter Tierzellen und seine Verwendung
AU2003217700A1 (en) 2002-02-26 2003-09-09 Stelsys Llc Hepatocyte bioreactor system for long term culture of functional hepatocyte spheroids
US20050069572A1 (en) 2002-10-09 2005-03-31 Jennifer Elisseeff Multi-layered polymerizing hydrogels for tissue regeneration
CA2556169C (en) 2004-01-29 2011-11-22 Andrew Lees Use of amino-oxy functional groups in the preparation of vaccines
CN101068574B (zh) 2004-07-20 2012-07-18 伊索格尼斯股份有限公司 与自身抗原有关的自身免疫和疾病的特异性抑制
US8187621B2 (en) 2005-04-19 2012-05-29 Advanced Cardiovascular Systems, Inc. Methods and compositions for treating post-myocardial infarction damage
EP1886696A1 (en) 2006-08-03 2008-02-13 Endotis Pharma Conjugates of antithrombin binding oligosaccharide derivatives and therapeutic proteins
US8275594B2 (en) 2006-10-30 2012-09-25 The Regents Of The University Of Michigan Engineered scaffolds for intervertebral disc repair and regeneration and for articulating joint repair and regeneration
ES2322637B1 (es) 2007-06-26 2010-03-05 Universidad Del Pais Vasco Microparticulas de alginato modificado con rgd como sistema de liberacion de farmacos.
IL187707A0 (en) 2007-11-27 2008-11-03 Univ Ben Gurion Alginate scaffold in hepatectomy
WO2010030964A2 (en) 2008-09-12 2010-03-18 The Brigham And Women's Hospital, Inc. 3-dimensional multi-layered hydrogels and methods of making the same
WO2010056378A2 (en) 2008-11-14 2010-05-20 Histogen, Inc. Extracellular matrix compositions for the treatment of cancer
WO2011078990A1 (en) * 2009-12-14 2011-06-30 Benaroya Research Institute At Virginia Mason Hydrogels comprising hyaluronan and at least one t cell induction agent
US20120321665A1 (en) * 2009-12-14 2012-12-20 Benaroya Research Institute At Virginia Mason Compositions and methods for treating airway inflammatory diseases
WO2011163568A1 (en) 2010-06-24 2011-12-29 University Of Kansas Conjugates comprising an n-oxime bond and associated methods
EP2678048B1 (en) 2011-02-22 2018-11-21 Institut National de la Sante et de la Recherche Medicale (INSERM) Nano-reservoirs technology for use in bone and/or cartilage regeneration
EP2816964B1 (en) 2012-02-21 2023-12-27 Ben-Gurion University of The Negev Research and Development Authority Hydrogel system comprising spatially separated bioactive polypeptides
WO2017175229A1 (en) * 2016-04-07 2017-10-12 B.G. Negev Technologies And Applications Ltd. Polysaccharide compositions and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9125883B2 (en) * 2004-06-14 2015-09-08 Institut Francais De Recherche Pour L'exploitation De La Mer (Ifremer) Sulfated depolymerized derivatives of exopolysaccharides (EPS) from mesophilic marine bacteria, method for preparing same, and uses thereof in tissue regeneration
WO2007043050A2 (en) * 2005-10-11 2007-04-19 Ben-Gurion University Of The Negev Research And Development Authority Bioconjugates comprising sulfated polysaccharides and their uses
CN103002915A (zh) * 2010-04-13 2013-03-27 免疫创新治疗有限公司 抑制Treg细胞的方法和组合物
CN105611937A (zh) * 2013-06-18 2016-05-25 复制细胞生命科学公司 治疗皮肤的组合物和方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Inhibition of Angiogenesis Is Associated With Reduced Islet;N. Zhang;《INHIBITION OF ANGIOGENESIS》;20051231;第37卷(第10期);第4452-4457页 *
The influence of the sequential delivery of angiogenic factors from affinitybinding;Inbar Freeman;《Biomaterials》;20090430;第30卷(第11期);第2122-2131页 *
Transforming growth factor-beta 1 delivery from microporous scaffolds decreases inflammation post-implant and enhances function of transplanted islets;Jeffrey M.H.Liu;《Biomaterials》;20151202;第80卷;第11-19页 *
VEGF-conjugated alginate hydrogel prompt angiogenesis and improve;Nina Yin;《Materials Science and Engineering C》;20151104;第59卷;第958-964页 *

Also Published As

Publication number Publication date
IL260436B1 (en) 2023-04-01
WO2017118979A1 (en) 2017-07-13
EP3400074B1 (en) 2021-10-20
IL260436A (enExample) 2018-08-30
KR20180104646A (ko) 2018-09-21
EP3400074A4 (en) 2019-07-10
JP7033066B2 (ja) 2022-03-09
CN109069875A (zh) 2018-12-21
JP2019504832A (ja) 2019-02-21
US11123404B2 (en) 2021-09-21
US20190008924A1 (en) 2019-01-10
EP3400074A1 (en) 2018-11-14
IL260436B2 (en) 2023-08-01

Similar Documents

Publication Publication Date Title
CN109069875B (zh) 产生免疫耐受反应的组合物和方法
US20220265779A1 (en) Enhancement of skeletal muscle stem cell engraftment by dual delivery of vegf and igf-1
Kim et al. Heparin functionalized injectable cryogel with rapid shape-recovery property for neovascularization
Andorko et al. Designing biomaterials with immunomodulatory properties for tissue engineering and regenerative medicine
Passipieri et al. Keratin hydrogel enhances in vivo skeletal muscle function in a rat model of volumetric muscle loss
JP5496675B2 (ja) 細胞移植療法に用いられる心疾患治療薬
TWI607760B (zh) 含膠原蛋白與透明質酸的細胞組織膠體
JP2022514568A (ja) 免疫系のモジュレーションのための生物工学的スキャフォールドおよびその使用
EP3065701B1 (en) Eluting matrix and uses thereof
Long et al. Decellularized extracellular matrix (d-ECM): the key role of the inflammatory process in pre-regeneration after implantation
Schackel et al. Peptides and astroglia improve the regenerative capacity of alginate gels in the injured spinal cord
Orr et al. TGF-β affinity-bound to a macroporous alginate scaffold generates local and peripheral immunotolerant responses and improves allocell transplantation
Ge et al. The soluble and particulate form of alginates positively regulate immune response
Liu et al. Impact of marine-based biomaterials on the immunoregulatory properties of bone marrow-derived mesenchymal stem cells: potential use of fish collagen in bone tissue engineering
US20170290954A1 (en) Compositions and methods for treating spinal cord injury
Safina et al. Cell-Biomaterial constructs for wound healing and skin regeneration
JP2018534353A (ja) 感染の防御を提供する軟組織増大のための組成物
WO2017175229A1 (en) Polysaccharide compositions and uses thereof
US20200323784A1 (en) Use of cxcl12 to promote survival, function, and immunoisolation of stem cell-derived beta cells
Carnes Tuning the Biophysical and Biochemical Cues of Fibrin Microthread Scaffolds Towards the Treatment of Volumetric Muscle Loss
US20220016219A1 (en) Means and Methods to Treat Diabetes
Kwee Biomaterial-based Helper T-cell Therapies for Ischemic Diseases
Su Design of Immunoactive Biomaterials for Therapeutic Applications
JP6429237B2 (ja) 免疫寛容部位形成剤及び免疫抑制性細胞の誘引剤
Chiu Angiogenesis in Patches and Injectable Biomaterials for Cardiac Repair

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20211224